Targeting Cells in Autophagy Process May Be Path to Halting Fibrosis, Study Suggests
Impaired autophagy — cells’ self-cleansing process — in the lungs’ epithelial cells may activate their epithelial-mesenchymal transition (EMT), a process crucial to the progression of fibrosis, according to a new study. The finding suggests that therapies targeting EMT may help halt fibrosis in idiopathic pulmonary fibrosis (IPF).
The study, “Autophagy inhibition-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis,” was published in the journal Cell Death & Disease.
Aging is a risk factor for IPF, as the incidence of the disease is known to increase with age. Aging carries detrimental effects to several cellular mechanisms, including the cells’ autophagy.
Autophagy is a natural mechanism used by cells to deliver malfunctioning or damaged cellular components for destruction in acidic vesicles called lysosomes. Analysis of tissue from IPF patients has shown that the autophagy response is impaired in these patients.
However, it remains unclear whether “faulty autophagy exerts an effect directly, or if this change is merely coincident with IPF,” researchers wrote.
To address this question, researchers at the University of Southampton, U.K., investigated whether autophagy activity is impaired in IPF tissue samples.
The Pulmonary Fibrosis News forums are a place to connect with other patients, share tips and talk about the latest research. Check them out today!
The team first confirmed that autophagy indeed is inhibited in lung epithelial cells in IPF samples. Then, researchers investigated how altered autophagy affected cells of the lung epithelium — alveolar epithelial cells.
They treated the cells with an autophagy inhibitor, called hydroxy-chloroquine, and saw that the treatment changed the cell’s behavior; specifically it activated the so-called epithelial-mesenchymal transition. EMT is a process by which epithelial cells gain migratory and invasive properties to become mesenchymal stem cells. EMT plays a critical role in the development of pulmonary fibrosis.
Researchers then tested another autophagy inhibitor, called bafilomycin-A1, and again saw that blocking autophagy triggered EMT. The same happened when they used a molecular approach and decreased the levels of key autophagy genes.
The team then investigated the role of EMT activation in alveolar epithelial cells in the context of fibrosis. Using a molecular strategy to decrease autophagy and induce EMT, researchers found these cells showed no enhanced ability to produce extracellular matrix components.
“This suggested ECM [extracellular matrix components] production in IPF lung tissue was unlikely due directly to EMT, but rather epithelial cells exhibiting an indirect effect on fibrogenesis [fibrosis development],” researchers wrote.
They found that these cells secreted factors that promoted fibroblasts’ transition into myofibroblasts, the cells responsible for the synthesis and buildup of scar tissue (fibrosis).
Overall, the “data suggest that reduced autophagy induces EMT of alveolar epithelial cells, and can contribute to fibrosis via aberrant epithelial–fibroblast crosstalk,” researchers wrote.
Targeting of EMT “might have therapeutic potential in fibrotic conditions,” the team suggested.